Table 1

Demographic features, cancer types, immunotherapy and rheumatic immune-related adverse events (irAEs)

Patient	Age	Sex	Malignancy	Immunotherapy	irAE	Serology	Time to onset (weeks)	Treatment	Improvement	Immunotherapy held for irAE
1	74	F	NSCL	Nivolumab	Arthritis	ANA 1:160 Anti-dsDNA 77	7.3	Prednisone 40 mg	Significant	Y
2	49	F	Melanoma	Ipilimumab Pembrolizumab	Arthritis		52.7	Prednisone 20 mg HCQ	Moderate	Y
3	42	F	RCC	Ipilimumab/nivolumab	Arthritis		3	Prednisone Infliximab, MTX Etanercept	Moderate	N
4	57	M	RCC	Ipilimumab/nivolumab	Arthritis	RF 214	48.4	Prednisone MTX Etanercept Adalimumab	Significant	N
5	59	F	Melanoma	Ipilimumab/nivolumab	Arthritis		21.7	Prednisone 60 mg	Minimal	N
6	81	M	Melanoma	Ipilimumab/nivolumab	Arthritis	ANA 1.5	13.1	Prednisone 15 mg	Moderate	Y
7	57	F	Melanoma	Ipilimumab/nivolumab	Arthritis Sicca	ANA 1:320	6.7	Prednisone 30 mg	Significant	Y
8	61	M	Melanoma	Ipilimumab/nivolumab	Sicca		5.3	Prednisone 60 mg*	Significant	Y†
9	63	M	RCC	Atezolizumab	Sicca		21.9	Prednisone 60 mg*	Significant	Y†
10	68	M	Melanoma	Ipilimumab/nivolumab	Sicca PMR	ANA 1:1280 SSA	8.1	Prednisone 30 mg	Significant	Y
11	79	M	Melanoma	Nivolumab	PMR Sicca		2	Prednisone 20 mg	Moderate	Y
12	63	M	RCC	Nivolumab	PMR		213	Prednisone 40 mg Infliximab	Minimal	Y
13	68	M	NSCL	Tremelimumab Durvalumab	Myositis		4.6	IV methylpred Prednisone 60 mg	Moderate	Y

*Prednisone given for hypophysitis.
†Immunotherapy held for hypophysitis.
Atezolizumab, anti-PD-L1; durvalumab, anti-PD-L1; HCQ, hydroxychloroquine; MTX, methotrexate; NSCL, non-small cell lung cancer; PMR, polymyalgia rheumatica; RCC, renal cell carcinoma; RF, rheumatoid factor; tremelimumab, anti-CTLA-4.